← Back to Screener
BioRestorative Therapies, Inc. Common Stock (NV) (BRTX)
Price$0.26
Favorite Metrics
Price vs S&P 500 (26W)-92.47%
Price vs S&P 500 (4W)-15.28%
Market Capitalization$6.72M
All Metrics
Book Value / Share (Quarterly)$0.04
P/TBV (Annual)1.25x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)44.18%
Cash Flow / Share (Quarterly)$-1.23
Price vs S&P 500 (YTD)-81.70%
Gross Margin (TTM)93.37%
Net Profit Margin (TTM)-3959.41%
EPS (TTM)$-1.61
10-Day Avg Trading Volume1.67M
EPS Excl Extra (TTM)$-1.61
Revenue Growth (5Y)35.07%
EPS (Annual)$-1.58
ROI (Annual)-3992.26%
Gross Margin (Annual)93.37%
Net Profit Margin (5Y Avg)-23470.44%
Cash / Share (Quarterly)$0.33
Revenue Growth QoQ (YoY)-54.73%
ROA (Last FY)-349.10%
Revenue Growth TTM (YoY)-10.30%
EBITD / Share (TTM)$-1.59
ROE (5Y Avg)-904.71%
Operating Margin (TTM)-4350.05%
Cash Flow / Share (Annual)$-1.23
P/B Ratio18.83x
P/B Ratio (Quarterly)29.23x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)14.48x
Net Interest Coverage (TTM)-23.34x
ROA (TTM)-199.43%
EPS Incl Extra (Annual)$-1.58
Current Ratio (Annual)0.84x
Quick Ratio (Quarterly)0.80x
3-Month Avg Trading Volume6.58M
52-Week Price Return-84.75%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.21
P/S Ratio (Annual)18.68x
Asset Turnover (Annual)0.09x
52-Week High$2.04
Operating Margin (5Y Avg)-23650.23%
EPS Excl Extra (Annual)$-1.58
CapEx CAGR (5Y)21.56%
26-Week Price Return-83.72%
Quick Ratio (Annual)0.80x
13-Week Price Return-77.65%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)0.84x
Enterprise Value$5.207
Revenue / Share Growth (5Y)-27.89%
Asset Turnover (TTM)0.05x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)21.00x
Pretax Margin (Annual)-3959.41%
Cash / Share (Annual)$0.33
3-Month Return Std Dev187.57%
Gross Margin (5Y Avg)89.02%
Net Income / Employee (TTM)$-1
ROE (Last FY)-3992.26%
Net Interest Coverage (Annual)-107.00x
EPS Basic Excl Extra (Annual)$-1.58
Receivables Turnover (TTM)3.53x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.61
Receivables Turnover (Annual)3.53x
ROI (TTM)-420.31%
P/S Ratio (TTM)18.68x
Pretax Margin (5Y Avg)-23470.44%
Revenue / Share (Annual)$0.04
Tangible BV / Share (Annual)$1.14
Price vs S&P 500 (52W)-119.85%
Year-to-Date Return-77.56%
5-Day Price Return2.65%
EPS Normalized (Annual)$-1.58
ROA (5Y Avg)-162.94%
Net Profit Margin (Annual)-3959.41%
Month-to-Date Return-3.09%
Cash Flow / Share (TTM)$-3.99
EBITD / Share (Annual)$-1.59
Operating Margin (Annual)-4350.05%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-904.24%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.61
P/TBV (Quarterly)7.01x
P/B Ratio (Annual)29.23x
Inventory Turnover (TTM)31.00x
Pretax Margin (TTM)-3959.41%
Book Value / Share (Annual)$0.04
Price vs S&P 500 (13W)-80.52%
Beta0.31x
Revenue / Share (TTM)$0.04
ROE (TTM)-420.31%
52-Week Low$0.19
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
4.13
Industry Peers — Health Services(14)
| Symbol | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|
BRTXBioRestorative Therapies, Inc. Common Stock (NV) | — | -10.30% | -4350.05% | -420.31% | $0.26 |
FMSFresenius Medical Care AG | 11.75x | 1.51% | 9.31% | 7.26% | $23.18 |
DVADaVita Inc. | 13.37x | 6.46% | 14.88% | 181.22% | $149.33 |
SHCSotera Health Company Common Stock | 59.47x | 5.74% | 25.41% | 14.98% | $16.28 |
PGNYProgyny, Inc. Common Stock | 24.25x | 10.40% | 6.62% | 11.37% | $18.64 |
AGLagilon health, inc. | — | -2.11% | -7.81% | -116.65% | $28.30 |
MCTACharming Medical Limited Class A Ordinary Shares | 414.66x | — | 15.45% | — | $29.36 |
VMDViemed Healthcare, Inc. Common Shares | 24.97x | 20.52% | 8.49% | 10.87% | $9.66 |
QIPTQuipt Home Medical Corp. Ordinary Shares | — | 9.52% | -1.22% | -10.47% | $3.65 |
PARKPark Dental Partners, Inc. Common Stock | 17.91x | — | 0.10% | — | $18.25 |
OAKUOak Woods Acquisition Corporation Class A Ordinary Shares | 174.54x | — | — | -0.64% | $12.20 |
About
BioRestorative Therapies is a biotechnology company developing cell-based regenerative medicine therapies using adult stem cells. The company is advancing BRTX-100, an autologous mesenchymal stem cell therapy for disc and spine disorders, and a brown adipose-derived cell therapy program targeting obesity and metabolic diseases.